Página principal > Artículos > Resultados de la búsqueda: Cortes, Javier

Artículos

  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Artículos Encontrados 30 registros  anterior11 - 20siguiente  ir al registro: La búsqueda tardó 0.01 segundos. 
11.
10 p, 1.8 MB Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals / Feliciano, Andrea (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; González, Lucila (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia Mayea, Yoelsis (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Mir, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Artola, Mireia (Primary Care Center CAP-Vallcarca-Sant Gervasi) ; Barragán-Brun, Nieves (Primary Care Center CAP-Vallcarca-Sant Gervasi) ; Martín, Remedios (Primary Care Center CAP-Vallcarca-Sant Gervasi) ; Altés, Anna (Primary Care Center CAP-Vallcarca-Sant Gervasi) ; Castellvi, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Benavente, Sergi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Rubio, Isabel T. (Clínica Universidad de Navarra) ; LLeonart, Matilde E. (Spanish Biomedical Research Network Center in Oncology) ; Universitat Autònoma de Barcelona
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. [...]
2020 - 10.3389/fonc.2020.586268
Frontiers in Oncology, Vol. 10 (november 2020)  
Registro completo - Creative Commons
12.
14 p, 1.4 MB Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer : a pilot clinical trial / Quintela-Fandino, Miguel (Hospital Universitario Quiron. Medical Oncology Department) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; Manso, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Morales, Serafin (Hospital Arnau de Vilanova (València)) ; Bermejo, Begoña (Centro de Investigación Biomédica en Red de Cáncer) ; Colomer, Ramon (Universidad Autónoma de Madrid. Facultad de Medicina) ; Apala, Juan V. (Hospital Universitario de Fuenlabrada ( Madrid)) ; Blanco, Raquel (Centro Nacional de Biotecnología/CSIC. Department of Immunology and Oncology) ; Muñoz, Manuel (Breast Cancer Clinical Research Unit - Clinical Research Program, CNIO - Spanish National Cancer Research Center) ; Caleiras, Eduardo (Histopathology Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Iranzo, Vega (Universitat de València. Departament de Medicina) ; Martínez López, Mario (Hospital Universitario 12 de Octubre (Madrid)) ; Dominguez, Orlando (Genomics Core Unit - Biotechnology Program, CNIO - Spanish National Cancer Research Center) ; Hornedo, Javier (Hospital Universitario Quiron. Medical Oncology Department) ; Gonzalez-Cortijo, Lucia (Hospital Universitario Quiron. Medical Oncology Department) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Gasol Cudos, Ariadna (Hospital Arnau de Vilanova (València)) ; Malon, Diego (Hospital Universitario de Fuenlabrada ( Madrid)) ; Lopez-Alonso, Antonio (Spanish National Cancer Research Center) ; Moreno-Ortíz, María C. (Centro Nacional de Biotecnología/CSIC) ; Mouron, Silvana (Spanish National Cancer Research Center) ; Mañes, Santos (Centro Nacional de Biotecnología/CSIC) ; Universitat Autònoma de Barcelona
Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. [...]
2020 - 10.1186/s13058-020-01362-y
Breast cancer research, Vol. 22 (november 2020)  
Registro completo - Creative Commons
13.
10 p, 621.9 KB Obesity and Breast Cancer : a Paradoxical and Controversial Relationship Influenced by Menopausal Status / García-Estévez, Laura (Centro de Investigación Biomédica en Red de Cáncer) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Pérez, Silvia (Breast Cancer Department, MD Anderson Cancer Center) ; Calvo Plaza, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ; Gallegos, Isabel (Breast Cancer Department, MD Anderson Cancer Center) ; Moreno-Bueno, Gema (MD Anderson International Foundation) ; Universitat Autònoma de Barcelona
Breast cancer is the most common tumor in women worldwide, and an increasing public health concern. Knowledge of both protective and negative risk factors is essential for a better understanding of this heterogenous disease. [...]
2021 - 10.3389/fonc.2021.705911
Frontiers in Oncology, Vol. 11 (august 2021)  
Registro completo - Creative Commons
14.
8 p, 1.1 MB Oncological care organisation during COVID-19 outbreak / Onesti, Concetta Elisa (University of Liège. Giga Research Institute) ; Rugo, Hope S. (University of California San Francisco. Department of Medicine) ; Generali, Daniele (University of Trieste) ; Peeters, Marc (University Hospital Antwerp (Bèlgica)) ; Zaman, Khalil (CHUV-Centre Hospitalier Universitaire Vaudois. Oncology Department) ; Wildiers, Hans (University Hospitals Leuven (Bèlgica)) ; Harbeck, Nadia (Ludwig Maximilians University Hospital) ; Martin, Miguel (Universidad Complutense de Madrid. Departamento de Medicina) ; Cristofanilli, Massimo (Northwestern University) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Tjan-Heijnen, Vivianne (Maastricht University Medical Center) ; Hurvitz, Sara A. (University of California Los Angeles) ; Berchem, Guy (Centre Hospitalier de Luxembourg. Hemato-Oncology Department) ; Tagliamento, Marco (Ospedale Policlinico San Martino) ; Campone, Mario (Institut de Cancérologie de l'Ouest. Centre René Gauducheau) ; Bartsch, Rupert (Medical University of Vienna) ; De Placido, Sabino (Università Degli Studi di Napoli Federico II.) ; Puglisi, Fabio (Centro di Riferimento Oncologico) ; Rottey, Sylvie (Uz Gent) ; Müller, Volkmar (University Medical Center Hamburg-Eppendorf) ; Ruhstaller, Thomas (Breast Center of Eastern Switzerland) ; Machiels, Jean-Pascal (Cliniques Universitaires St. Luc) ; Conte, Pierfranco (University of Padova) ; Awada, Ahmad (Université Libre de Bruxelles) ; Jerusalem, Guy (Université de Liège) ; Universitat Autònoma de Barcelona
Background: COVID-19 appeared in late 2019, causing a pandemic spread. This led to a reorganisation of oncology care in order to reduce the risk of spreading infection between patients and healthcare staff. [...]
2020 - 10.1136/esmoopen-2020-000853
ESMO open, Vol. 5 Núm. 4 (august 2020) , p. e000853  
Registro completo - Creative Commons
15.
0 p, 170.6 KB Commentary : SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China / Di Cosimo, Serena (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano) ; Porcu, Luca (Istituto di Ricerche Farmacologiche Mario Negri IRCCS) ; Malfettone, Andrea (Medica Scientia Innovation Research (New Jersey, Estats Units d'Amèrica)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. Department of Applied Research and Technological Development) ; Universitat Autònoma de Barcelona
2020 - 10.3389/fonc.2020.01223
Frontiers in Oncology, Vol. 10 (july 2020) , p. 1223  
Registro completo - Creative Commons
16.
9 p, 1.7 MB Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design / Sampayo-Cordero, Miguel (Medica Scientia Innovation Research (MedSIR)) ; Miguel-Huguet, Bernat (Hospital Universitari de Bellvitge) ; Pérez-García, José (QuironSalud Group) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Guerrero-Zotano, Ángel L. (Vanderbilt University Medical Center) ; Garde-Noguera, Javier (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Aguirre, Elena (Hospital Quirónsalud Zaragoza) ; Holgado, Esther (Hospital Universitario Ramón y Cajal (Madrid)) ; López-Miranda, Elena (Hospital Universitario Ramón y Cajal (Madrid)) ; Huang, Xin (Pfizer Global Research and Development) ; Malfettone, Andrea (Medica Scientia Innovation Research (MedSIR)) ; Llombart-Cussac, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Non-inferiority (NI) analysis is not usually considered in the early phases of clinical development. In some negative phase II trials, a post-hoc NI analysis justified additional phase III trials that were successful. [...]
2020 - 10.1016/j.conctc.2020.100678
Contemporary Clinical Trials Communications, Vol. 20 (november 2020)  
Registro completo - Creative Commons
17.
13 p, 6.8 MB Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity / Prat, Aleix (Vall d'Hebron Institut d'Oncologia) ; Adamo, Barbara (Vall d'Hebron Institut d'Oncologia) ; Fan, Cheng (Lineberger Comprehensive Cancer Center, University of North Carolina) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Vidal Losada, Maria (Vall d'Hebron Institut d'Oncologia) ; Galván, Patricia (Vall d'Hebron Institut d'Oncologia) ; Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ; Palmer, Héctor G. ; Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ; Dawood, Shaheenah (Department of Medical Oncology, Dubai Hospital) ; Rodón, Jordi (Vall d'Hebron Institut d'Oncologia) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron) ; Campo, Josep Maria Del (Vall d'Hebron Institut d'Oncologia) ; Felip, Enriqueta (Vall d'Hebron Institut d'Oncologia) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). [...]
2013 - 10.1038/srep03544
Scientific reports, Vol. 3 (december 2013)  
Registro completo - Creative Commons
18.
14 p, 3.0 MB The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 / Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ; Escrivá-de-Romaní, Santiago (Hospital Universitari Vall d'Hebron) ; Bernadó Morales, Cristina (Vall d'Hebron Institut d'Oncologia) ; Luque, Antonio (Vall d'Hebron Institut d'Oncologia) ; Escorihuela, Marta (Vall d'Hebron Institut d'Oncologia) ; Espinosa-Bravo, Martín (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron) ; Dijcks, Fred A. (Preclinical R&D, The Netherlands) ; Dokter, Wim H. A. (Preclinical R&D, The Netherlands) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Saura, Cristina (Hospital Universitari Vall d'Hebron) ; Arribas, Joaquín V (Institució Catalana de Recerca i Estudis Avançats) ; Universitat Autònoma de Barcelona
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) approved for the treatment of HER2 (human epidermal growth factor receptor 2)-positive breast cancer. T-DM1 consists of trastuzumab covalently linked to the cytotoxic maytansinoid DM1 via a non-cleavable linker. [...]
2020 - 10.3390/cancers12030670
Cancers, Vol. 12 (march 2020)  
Registro completo - Creative Commons
19.
12 p, 615.6 KB ESMO Management and treatment adapted recommendations in the COVID-19 era : Breast Cancer / Azambuja, Evandro de (Institut Jules Bordet and l'Université Libre de Bruxelles) ; Trapani, Dario (European Institute of Oncology) ; Loibl, Sibylle (GBG Forschungs GmbH) ; Delaloge, Suzette (Gustave Roussy and Paris-Saclay University) ; Senkus, Elzbieta (Department of Oncology and Radiotherapy. Medical University of Gdańsk) ; Criscitiello, Carmen (European Institute of Oncology) ; Poortman, Philip (Iridium Kankernetwerk and University of Antwerp) ; Gnant, Michael (Comprehensive Cancer Center. Medical University of Vienna) ; Di Cosimo, Serena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Paluch-Shimon, Shani (Shaare Zedek Medical Centre) ; Curigliano, Giuseppe (Department of Oncology and Hemato-Oncology. University of Milano) ; Universitat Autònoma de Barcelona. Departament de Medicina
The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. [...]
2020 - 10.1136/esmoopen-2020-000793
ESMO open, Vol. 5 (20 2020) , p. e000793  
Registro completo - Creative Commons
20.
30 p, 7.5 MB The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer / De Mattos-Arruda, Leticia (Vall d'Hebron Institut d'Oncologia) ; Sammut, Stephen-John (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Ross, Edith M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Bashford-Rogers, Rachael (Department of Medicine. University of Cambridge) ; Greenstein, Erez (Weizmann Institute of Science (Israel). Department of Immunology) ; Markus, Havell (Mayo Clinic Center for Individualized Medicine) ; Morganella, Sandro (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Teng, Yvonne (Cancer Molecular Diagnosis Laboratory. NIHR Cambridge Biomedical Research Centre) ; Maruvka, Yosef (Massachusetts General Hospital (Boston)) ; Pereira, Bernard (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Rueda, Oscar M. (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Chin, Suet-Feung (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Contente-Cuomo, Tania (Mayo Clinic Center for Individualized Medicine) ; Mayor, Regina (Centro de Investigación Biomédica en Red de Cáncer) ; Arias, Alexandra (Vall d'Hebron Institut d'Oncologia) ; Ali, H. Raza (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Cope, Wei (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Tiezzi, Daniel (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Dariush, Aliakbar (Institute of Astronomy. University of Cambridge) ; Dias Amarante, Tauanne (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Reshef, Dan (Weizmann Institute of Science (Israel). Department of Immunology) ; Ciriaco, Nikaoly (Hospital Universitari Vall d'Hebron) ; Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron) ; Peg, Vicente (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ; Vassiliou, George (Wellcome Trust/MRC Cambridge Stem Cell Institute) ; Getz, Gad (Massachusetts General Hospital (Boston)) ; Nik-Zainal, Serena (Department of Medical Genetics. The Clinical School. University of Cambridge) ; Murtaza, Muhammed (Mayo Clinic Center for Individualized Medicine) ; Friedman, Nir (Weizmann Institute of Science (Israel). Department of Immunology) ; Markowetz, Florian (Department of Oncology and Cancer Research UK Cambridge Institute. Li Ka Shing Centre. University of Cambridge) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Caldas, Carlos (Cancer Research UK Cambridge Cancer Centre (Regne Unit)) ; Universitat Autònoma de Barcelona
The detailed molecular characterization of lethal cancers is a prerequisite to understanding resistance to therapy and escape from cancer immunoediting. We performed extensive multi-platform profiling of multi-regional metastases in autopsies from 10 patients with therapy-resistant breast cancer. [...]
2019 - 10.1016/j.celrep.2019.04.098
Cell reports, Vol. 27 Núm. 9 (28 2019) , p. 2690-2708.e10  
Registro completo - Creative Commons

Artículos : Encontrados 30 registros   anterior11 - 20siguiente  ir al registro:
Vea también: autores con nombres similares
1 Cortes, J
3 Cortes, J.
9 Cortes, Javier,
9 Cortes, Jordi
1 Cortès, Jacques
1 Cortés, J
3 Cortés, J.
42 Cortés, Javier
9 Cortés, Javier,
9 Cortés, Jordi
1 Cortés, Juan
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos